Anthropic’s IPO roadshow tests a less-than-decade AI cure claim

By Amara Osei

Anthropic CEO Dario Amodei said in a 42-minute IPO roadshow video released Tuesday: “cancer, Alzheimer's, heart disease, mental illness — these will be relics of the past in, I think, less than a decade.”

The forecast came as Anthropic moved toward an IPO only weeks away and sought a trillion-dollar valuation. Karl Lauterbach, Melinda B. Chu and biotech executive Rami Elghandour publicly rejected the timetable as unrealistic.

What does Anthropic’s medical strategy include?

Anthropic has expanded into drug development by buying several biotech startups. One acquisition was a one-person company focused on developing treatments for muscular dystrophy.

In an October blog post, Anthropic said it had “begun drug discovery efforts of our own.” A person familiar with the matter said the company also opened a “wet lab” in the Bay Area to explore how AI technology could support research in fundamental biology.

Amodei has long warned that bad actors could misuse AI. Business Insider reported that he had sought to soften his doomer reputation partly by highlighting AI’s potential benefits in medicine.

What did Amodei say before the roadshow?

In an August X post, Amodei said the best way to win over AI skeptics was for AI companies to “actually cure cancer.” He also warned that “saying that AI will cure cancer is more a cliché than it is inspiring, and most people think it is deceptive.”

His August position was more cautious than the roadshow claim, which added heart disease and mental illness to cancer and Alzheimer's. Amodei nevertheless tied medical progress to public trust, saying AI companies would win skeptics by actually delivering cures.

Why did medical researchers reject the forecast?

Some AI naysayers and physicians took to X after the video to voice disbelief. Their objections did not reject AI's potential in medicine; they challenged the timetable and Anthropic's readiness to deliver it.

On November 11, 2026, Karl Lauterbach, Germany's former health minister, wrote on X: “Curing cancer, Alzheimer's and mental illnesses can definitely benefit from AI. But that is impossible in just 10 years.” He added: “Unclear whether people like @DarioAmodei know so little about medicine or are deliberately misleading the public.” His post also called for a focus on prevention.

The objection did not dispute AI's medical value. Lauterbach instead placed prevention ahead of a promised cure inside a decade.

Melinda B. Chu, an AI medical researcher with an MD from Saint Louis University, said Amodei made the prediction to stoke hype for Anthropic's IPO. Chu said Anthropic had done nothing to suggest it would contribute meaningfully to the goals Amodei predicted.

Rami Elghandour, a biotech executive who has taken two companies public, said the forecast reeked of desperation. “I've taken two companies public. These are insane things to say in an IPO pitch and wreaks of desperation,” he said.

The objections targeted three separate risks: Lauterbach questioned the clinical timetable, Chu challenged Anthropic's scientific contribution and Elghandour questioned the salesmanship of the claim. Lauterbach and Elghandour posted their objections on X on November 11, 2026.

Why does the IPO make the claim more consequential?

The IPO is only weeks away, according to Business Insider, and Anthropic wants investors to buy stock at a trillion-dollar valuation. Amodei said in the video: “I think if we do this right, we can create an age of miracles.”

Business Insider said Amodei's calculus had apparently shifted as the IPO neared. His remarks made medicine central to the pitch for public trust.

The medical promise now accompanies the valuation case at the center of Anthropic's IPO effort. The company has publicly said it has begun drug discovery, and a person familiar with its work said Anthropic opened the Bay Area lab.

With the IPO weeks away, Anthropic must defend a trillion-dollar valuation alongside a sweeping medical claim. The burden is concrete: Chu said, “Anthropic has done nothing to suggest they themselves will contribute meaningfully to these goals.”